Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08CLA
|
|||
Drug Name |
PMID25666693-Compound-123
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
Company |
PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
|
|||
Structure |
Download2D MOL |
|||
Formula |
C21H21F3N4O3
|
|||
Canonical SMILES |
C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
|
|||
InChI |
1S/C21H21F3N4O3/c22-21(23,24)14-7-6-13(17(10-14)28-8-1-2-9-28)11-25-20(30)27-16-5-3-4-15-19(16)31-12-18(29)26-15/h3-7,10H,1-2,8-9,11-12H2,(H,26,29)(H2,25,27,30)
|
|||
InChIKey |
ABNCWKBVNWSWPZ-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Inflammatory mediator regulation of TRP channels | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
Reactome | TRP channels |
References | Top | |||
---|---|---|---|---|
REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.